Migraine Preventive Drug Gets EU Nod for Acute Episodes

by admin | Apr 27, 2026 | Health

Spread the love

The EMA has endorsed Aquipta, an oral CGRP receptor antagonist, after it showed superior pain relief vs placebo in treating migraine attacks in adults.
Medscape News Europe

← Indonesia-US overflight debate misses the strategic point ‘Kindness is in the Philippines' DNA’: Communities offer meals, aid to drivers hit by soaring fuel prices →

Written By

Written by Albert Pham, News Curator and Blogger

McDonald’s Chicken and Beverage Strategy: Global Growth Plans Through 2030

Oct 12, 2026 | albertpham, Economy_finances, Health

McDonald’s is expanding its chicken menu and specialty beverages to gain market share by 2030, challenge competitors and attract more customers.

Endometriosis in Canada: Why Women Are Seeking Treatment in Mexico

Oct 12, 2026 | albertpham, Health, Travel

Canadian women are travelling to Mexico for endometriosis treatment after facing long wait times, highlighting gaps in specialist care and women’s health services.

Type 2 Diabetes Symptoms: 5 Early Warning Signs to Know

Oct 12, 2026 | albertpham, Health

Frequent thirst, fatigue, blurred vision and unexplained weight changes may signal type 2 diabetes. Learn the warning signs and when to seek medical advice.

Migraine Preventive Drug Gets EU Nod for Acute Episodes

Written By

Related Posts

McDonald’s Chicken and Beverage Strategy: Global Growth Plans Through 2030

Endometriosis in Canada: Why Women Are Seeking Treatment in Mexico

Type 2 Diabetes Symptoms: 5 Early Warning Signs to Know

0 Comments

Explore More

Connect With Us

Quick Links

Legal

Stay Updated